Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No sweat for BioMarin at Vimizim panel; well, maybe a little

This article was originally published in Scrip

Executive Summary

If the members of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) are as placid as the agency seemingly appeared to be in briefing documents released ahead of the 19 November meeting of the outside advisers, BioMarin Pharmaceutical won't have much to sweat over, although that doesn't mean regulators didn’t raise some issues for the panel to sink its teeth into in mulling over the data for Vimizim (elosulfase alfa), an enzyme replacement treatment (ERT).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel